Skip navigation
University library of Heidelberg
Availability: reference only

Verfügbarkeit
Location: ---
Copies: ---
heiBIB
 Online resource
Verfasst von:Radu, Christian Andreas [VerfasserIn]   i
 Kiefer, Jurij [VerfasserIn]   i
 Horn, Dominik [VerfasserIn]   i
 Kleist, Christian [VerfasserIn]   i
 Dittmar, Laura [VerfasserIn]   i
 Şandra-Petrescu, Flavius Ionuţ [VerfasserIn]   i
 Ryssel, Henning [VerfasserIn]   i
 Köllensperger, Eva [VerfasserIn]   i
 Gebhard, Martha-Maria [VerfasserIn]   i
 Lehnhardt, Marcus [VerfasserIn]   i
 Germann, Günter [VerfasserIn]   i
 Terness, Peter [VerfasserIn]   i
Titel:Mitomycin-C-treated peripheral blood mononuclear cells (PBMCs) prolong allograft survival in composite tissue allotransplantation
Verf.angabe:Christian Andreas Radu, Jurij Kiefer, Dominik Horn, Christian Kleist, Laura Dittmar, Flavius Sandra, Martin Rebel, Henning Ryssel, Eva Koellensperger, Martha M. Gebhard, Marcus Lehnhardt, Guenter Germann, and Peter Terness
E-Jahr:2012
Jahr:August 2012
Umfang:7 S.
Fussnoten:Gesehen am 26.11.2018
Titel Quelle:Enthalten in: Journal of surgical research
Ort Quelle:Orlando, Fla. : Academic Press, 1961
Jahr Quelle:2012
Band/Heft Quelle:176(2012), 2, Seite e95-e101
ISSN Quelle:1095-8673
Abstract:Background: Composite tissue allotransplantation (CTA) was introduced as a potential treatment for complex reconstructive procedures and has become a clinical reality. Hand and face transplantation, the most widely recognized forms of CTA, have intensified immunological research in this emerging field of transplantation. Mitomycin C (MMC) is an alkylating agent that suppresses allogeneic T-cell responses. MMC-treated dendritic cells/PBMCs have been shown to induce donor-specific tolerance in solid organ allograft transplantations. Methods: Fully mismatched rats were used as hind limb donors [Lewis (RT11)] and recipients [Brown-Norway (RT1n)]. Fifty-five allogeneic hind limb transplantations were accomplished in six groups. Group A (n = 10) received donor-derived MMC-treated PBMCs on transplantation day. Group B (n = 10) rats received no immunosuppression, group C (n = 10) received FK506 and prednisolon, group D consisted in isograft transplantation without immunosuppression, group E (n = 10) received non-treated PBMCs, and group F (n = 5) received PBS without any donor-derived cells. Rejection was assessed clinically and histologically. Results: In group A, the survival times of the allografts were prolonged to an average of 8.0 d. Rejection was significantly delayed compared with the averages of the corresponding control groups B, E, and F (5.5, 5.9, and 5.8 d). No rejection was seen in control groups C and D. Conclusion: These results demonstrate that MMC-treated donor PBMCs significantly prolong allograft survival when administered systemically on the day of transplantation. However, the immunomodulatory effect is relatively modest with further research being required to clarify dose-effect relations, cell characteristics, and an optimized mechanism and timing for cell application.
DOI:doi:10.1016/j.jss.2011.12.032
URL:Bibliographic entry. University members only receive access to full-texts for open access or licensed publications.

Volltext: http://dx.doi.org/10.1016/j.jss.2011.12.032
 Volltext: http://www.sciencedirect.com/science/article/pii/S0022480411020403
 DOI: https://doi.org/10.1016/j.jss.2011.12.032
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Composite tissue allotransplantation
 CTA
 Mitomycin
 PBMC
 Peripheral blood mononuclear cells
 Tolerance
K10plus-PPN:1584434104
Verknüpfungen:→ Journal

Permanent link to this item:  https://katalog.ub.uni-heidelberg.de/titel/68332319   QR-Code
zum Seitenanfang